Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.6K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.6K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.9K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

991
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
991
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

690
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
690
Tonsillitis II: Management01:26

Tonsillitis II: Management

626
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
626
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

1.2K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and management of immune checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Nanoplastics perturb extracellular vesicle-mediated communication in the in vitro and ex vivo bone marrow microenvironment of multiple myeloma.

Journal of hazardous materials·2026
Same author

Detection of human papillomavirus infection in oral mucosal diseases: A single-center study.

JADA foundational science·2026
Same author

Spatiotemporal atlas of pro-inflammatory NF-κB and anti-inflammatory STAT6 signaling using reporter mice during mRNA vaccination.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K

Mucositis: pathobiology and management.

Alessandro Villa1, Stephen T Sonis

  • 1Division of Oral Medicine and Dentistry, Brigham and Women's Hospital Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.

Current Opinion in Oncology
|March 17, 2015
PubMed
Summary
This summary is machine-generated.

Oral mucositis, a severe side effect of cancer therapy, lacks effective treatments. Research is advancing understanding of its causes and developing targeted therapies and risk prediction tools.

More Related Videos

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Related Experiment Videos

Last Updated: Apr 16, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

5.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Area of Science:

  • Oncology
  • Oral Medicine
  • Pharmacology

Background:

  • Oral mucositis (OM) is a debilitating toxicity from cancer treatments.
  • It significantly impacts patient quality of life and treatment adherence.

Purpose of the Study:

  • To review recent advancements in understanding OM's biological basis.
  • To discuss risk factors and current management strategies for OM.
  • To highlight emerging therapeutic targets and predictive tools.

Main Methods:

  • Literature review of recent studies on oral mucositis.
  • Analysis of pathogenesis, epidemiology, and treatment modalities.

Main Results:

  • OM prevalence data are inconsistent and often underreported.
  • Pathogenesis involves complex biological events, potentially influenced by the oral microbiome.
  • No universally effective treatment currently exists for most at-risk patients.

Conclusions:

  • OM is a common, impactful cancer treatment complication.
  • Effective interventions are lacking, causing patient and caregiver distress.
  • New mechanistically targeted compounds are under development, alongside risk prediction tools.